Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada

Next Previous
Search
Trial Profile

Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Aciclovir; Cetirizine; Esomeprazole; Ibuprofen; Methylprednisolone; Paracetamol; Ranitidine
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms EMERALD
  • Sponsors Genzyme Corporation

    • Most Recent Events

    • 08 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2015 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrial.gov.
    • 15 Jun 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrial.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top